|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses | |||||
| Research and development | |||||
| General and administrative | |||||
| In-process research and development | |||||
| Impairment of long-lived assets | |||||
| Impairment of goodwill | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other expense | |||||
| Interest expense | |||||
| Interest income | |||||
| Other income | |||||
| Total other income | |||||
| Loss before provision for income taxes | |||||
| (Benefit) provision for income taxes | |||||
| Net loss | |||||
| Unrealized gain (loss) on investments | |||||
| Foreign currency translation gain | |||||
| Comprehensive loss | |||||
| Net loss per common share Basic (in dollars per share) | |||||
| Net loss per common share Diluted (in dollars per share) | |||||
| Weighted average common shares outstanding Basic (in shares) | |||||
| Weighted average common shares outstanding Diluted (in shares) |
Loading...